OFI Invest Asset Management Has $26.57 Million Stake in Edwards Lifesciences Corporation $EW

Key Points

• OFI Invest Asset Management increased its stake in Edwards Lifesciences Corporation by 7.0%, now owning approximately $26.57 million worth of shares.
• Several analysts have set a price target range for Edwards Lifesciences between $82.00 and $95.00, with a consensus rating of "Moderate Buy."
• Insider selling activity included VP Daniel J. Lippis and insider Larry L. Wood reducing their share holdings, reflecting a 15.75% and 4.15% decrease respectively.

OFI Invest Asset Management raised its holdings in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 7.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 339,715 shares of the medical research company's stock after acquiring an additional 22,282 shares during the period. OFI Invest Asset Management owned about 0.06% of Edwards Lifesciences worth $26,569,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Quantbot Technologies LP acquired a new position in shares of Edwards Lifesciences during the first quarter worth about $26,000. SouthState Corp acquired a new position in shares of Edwards Lifesciences during the first quarter worth about $27,000. Global X Japan Co. Ltd. boosted its position in shares of Edwards Lifesciences by 116.1% during the first quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company's stock worth $29,000 after buying an additional 216 shares during the period. Tradewinds Capital Management LLC boosted its position in shares of Edwards Lifesciences by 102.5% during the first quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company's stock worth $29,000 after buying an additional 205 shares during the period. Finally, Rossby Financial LCC acquired a new position in shares of Edwards Lifesciences during the first quarter worth about $29,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, VP Daniel J. Lippis sold 4,114 shares of the firm's stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the completion of the sale, the vice president directly owned 22,002 shares of the company's stock, valued at $1,748,278.92. This trade represents a 15.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Larry L. Wood sold 8,950 shares of the firm's stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the sale, the insider directly owned 206,900 shares of the company's stock, valued at approximately $16,150,614. The trade was a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.29% of the company's stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on EW shares. Evercore ISI set a $88.00 price objective on Edwards Lifesciences and gave the stock an "outperform" rating in a research report on Tuesday. Wells Fargo & Company upped their price objective on Edwards Lifesciences from $84.00 to $88.00 and gave the stock an "overweight" rating in a research report on Thursday, August 7th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Edwards Lifesciences in a research report on Wednesday. Mizuho upped their price objective on Edwards Lifesciences from $87.00 to $95.00 and gave the stock an "outperform" rating in a research report on Friday, July 25th. Finally, Truist Financial upped their price objective on Edwards Lifesciences from $81.00 to $82.00 and gave the stock a "hold" rating in a research report on Friday, July 25th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Edwards Lifesciences presently has a consensus rating of "Moderate Buy" and a consensus price target of $87.06.

Edwards Lifesciences Stock Performance

Shares of NYSE EW opened at $74.02 on Friday. The stock has a 50 day moving average price of $78.09 and a 200 day moving average price of $76.13. Edwards Lifesciences Corporation has a 52 week low of $64.89 and a 52 week high of $83.00. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. The stock has a market capitalization of $43.46 billion, a PE ratio of 10.65, a price-to-earnings-growth ratio of 3.55 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company had revenue of $1.53 billion during the quarter, compared to analysts' expectations of $1.49 billion. During the same period last year, the firm posted $0.70 earnings per share. The business's revenue was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.